All In Biotech

Drug Trial Radar · NCT05600894

Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm

Venetoclax In Combination With ASTX727, an All-ORal TherapY for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): a Randomized, Phase 2 Trial

Last checked: Nov 20, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 132 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

132

Planned (sponsor's estimate)

Start

Jun 27, 2023

Primary completion

Aug 31, 2027

Study completion Aug 31, 2027

Sponsor

Sponsor type
NIH
First posted
Nov 1, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests whether decitabine and cedazuridine (ASTX727) in combination with venetoclax work better than ASTX727 alone at decreasing symptoms of bone marrow cancer in patients with chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) with excess blasts. Blasts are immature blood cells. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. The combination of ASTX727 and venetoclax may be more effective in reducing the cancer signs and symptoms in patients with CMML, or MDS/MPN with excess blasts.

Conditions

  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome With Excess Blasts
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Myeloproliferative Neoplasm

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of blood and buccal samples

  • Bone Marrow AspirationProcedure

    Undergo bone marrow aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy

  • Decitabine and CedazuridineDrug

    Given PO

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete response rateTime frame: Up to 4 cycles

Locations

34 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital in Arizona

    Phoenix, Arizona

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • UCI Health Laguna Hills

    Laguna Hills, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Yale University

    New Haven, Connecticut

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • Northwestern University

    Chicago, Illinois

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • UC Comprehensive Cancer Center at Silver Cross

    New Lenox, Illinois

  • University of Chicago Medicine-Orland Park

    Orland Park, Illinois

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas

  • University of Maryland/Greenebaum Cancer Center

    Baltimore, Maryland

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • NYP/Weill Cornell Medical Center

    New York, New York

  • Montefiore Medical Center-Einstein Campus

    The Bronx, New York

  • Montefiore Medical Center-Weiler Hospital

    The Bronx, New York

  • Montefiore Medical Center - Moses Campus

    The Bronx, New York

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina

  • University of Cincinnati Cancer Center-UC Medical Center

    Cincinnati, Ohio

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio

  • University of Cincinnati Cancer Center-West Chester

    West Chester, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Huntsman Cancer Institute/University of Utah

    Salt Lake City, Utah

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia

  • University Health Network-Princess Margaret Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.